Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer

计划入组 1,000 人 · 首次发布于 2022 年 2 月 22 日

Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients

计划入组 500 人 · 首次发布于 2026 年 6 月 1 日

Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

计划入组 189 人 · 首次发布于 2018 年 8 月 2 日

Programmed cell death protein 1 (PD-1)/PD-ligand-1 blockers (Hitgen)

TTX-siPDL1

Programmed cell death 1 antibody(Sun Yat-Sen University)

Ligand Pharmaceuticals

United States

NHI-1

United States

Xi'an No.1 Hospital

China

Optimizing Outcomes for High-Risk, Non-Muscle-Invasive Bladder Cancer with PD-(L)1 Inhibitors

AstraZeneca's Durvalumab Receives Indian Approval for Expanded NSCLC Treatment

Low Incidence of Cardiovascular Events with Immune Checkpoint Inhibitors Reported in Meta-Analysis